Several bispecific formats for CEACAM5 targeting were reported for cancer immunotherapy over the years such as an anti CEACAM5/CD3 BITE (MEDI-565/AMG 211) (44) or the head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors (45, 46) and others (47–49). The gene discussed is CEACAM5; the disease is cancer.